Univercells, Belgium based technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions declares the acceptance of €2.4M ($2.9M) grant from the Walloon Region.

This funding will enable the company to launch a program aimed at developing its innovative protein platform, paving the way for the cost-effective production of biosimilars. 

The new generation of biologic medicines represents significant progress in healthcare, successfully addressing oncology, auto-immune and rare diseases. 

The increasing demand for affordable biologics calls for adapted production capacities, capable of drastic cost containment for a significant impact on the commercial price. 

Univercells’ new program will focus on designing the next generation of production technologies, drastically reducing manufacturing costs while delivering large quantities, answering the growing demand for antibodies.

The resulting low-footprint high-capacity production units are more affordable to build and operate, improving worldwide access to high-quality biologics.